

[OPEN ACCESS](#)

ORIGINAL ARTICLE

Pak J Adv Med Med Res

## Exploring the Relationship Between Chronic Obstructive Pulmonary Disease and Serum Lipid Levels

Muhammad Ibrahim<sup>1</sup>, Mohammad Kamran Khalil<sup>2</sup>, Izhar Ahmad<sup>3</sup>

<sup>1</sup>Specialist Physician Med clinic Al Noor hospital Abu Dhabi UAE

<sup>2</sup>Department of Medicine King Abdullah Hospital Ksa

<sup>3</sup>Consultant Physician Medica hospital Male city Maldives

### ABSTRACT

**Background:** Chronic obstructive pulmonary disease (COPD) is a major global health problem associated with chronic inflammation, oxidative stress, and metabolic disturbances, including dyslipidemia. Dyslipidemia contributes to increased cardiovascular risk, which is commonly observed in COPD patients. Understanding the relationship between serum lipid levels and COPD severity is essential for comprehensive disease management.

**Objective:** To investigate the association between serum lipid profile and COPD severity, and to assess the correlation between dyslipidemia and disease progression.

**Methods:** A total of 100 patients diagnosed with COPD were included. Serum lipid parameters, including total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides, were measured. COPD severity was classified using GOLD criteria based on spirometry. Pearson correlation coefficient was applied to assess relationships between lipid levels and disease severity. A p-value < 0.05 was considered statistically significant.

### Results:

The study included 100 patients (60 males, 40 females) with a mean age of  $62 \pm 8$  years. Patients with severe COPD had significantly higher total cholesterol and LDL levels. Approximately 60% had low HDL (<40 mg/dL), while 40% had elevated triglycerides (>150 mg/dL). Increased LDL levels were significantly associated with greater COPD severity ( $p = 0.02$ ), and elevated triglycerides also showed a significant association ( $p = 0.03$ ).

### Conclusion:

Dyslipidemia is significantly associated with COPD severity. Comprehensive management of COPD should include evaluation and control of lipid abnormalities to reduce cardiovascular risk and improve patient outcomes.

**Keywords:** COPD; Dyslipidemia; Serum Lipids; Cardiovascular Risk

**How to Cite This Article:** Ibrahim M, Khalil MK, Ahmad I. Exploring the relationship between chronic obstructive pulmonary disease and serum lipid levels. Pak J Adv Med Med Res. 2025;3(2):64–69. [doi:10.69837/pjammr.v3i2.73](https://doi.org/10.69837/pjammr.v3i2.73).

**Corresponding Author:** Mohammad Kamran Khalil

Department of Medicine King Abdullah Hospital KSA

**Email:** [kamrankhalil824@gmail.com](mailto:kamrankhalil824@gmail.com)

**ORCID:** <https://orcid.org/0009-0009-7159-7274>

### OJS/Tracking

<b>Received:</b>	January	28-2025
<b>Revised:</b>	March	26-2025
<b>Accepted:</b>	May	30 -2025
<b>Published:</b>	July	10- 2025

## INTRODUCTION

Chronic obstructive pulmonary disease (COPD) has been one of the major causes of morbidity and mortality both globally and locally, with its characteristic persistent respiratory signs and airflow limits due to disfigurement of airways and/or abnormalities in the alveoli [1]. The systemic nature of COPD and the high prevalence of cardiovascular comorbidities highlight the importance of consideration of a full spectrum of risk factors of the disease overall rather than pulmonary functioning indexes [2]. Systemic inflammation mediated by dyslipidemia, a well-recognized modifiable risk factor of cardiovascular disease, has been implicated in many systemic inflammatory disorders, although the interaction between abnormal lipid profile levels and disease severity of COPD is poorly understood. There is emerging evidence to indicate that changes in serum lipid profiles are not merely the reprieve of systemic inflammation, but it can also have disease progression and comorbidity burden in known COPD patients [3]. In fact, total cholesterol, LDL, and triglycerides and low levels of HDL correlate with increased systemic inflammation, oxidative stress, and dysfunction of the endothelium, all of which causes increased morbidity of COPD [4]. Moreover, cardiovascular events are a leading cause of mortality in COPD, which highlights the clinical significance of lipid abnormalities among these patients. In the Middle East, where prevalence of COPD remains on the increase against the backdrop of elevated incidences of metabolic syndrome and dyslipidemia, there is a dearth of published evidence relating COPD severity to lipid abnormalities [5]. Little information exists about metabolic parameters of the system in scope of COPD overview, except the useful relationship of the serum lipids profile with the severity of the disease in the United Arab Emirates (UAE) [6]. To bridge this gap, we have conducted a cross-sectional study in Al Noor Hospital, Abu Dhabi in regards to the connection between serum lipid profiles and severity of COPD. We theorized that progressive severity of COPD as per the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria would correlate with sequent worse lipid profile that would include elevated levels of total cholesterol and LDLs and triglycerides and decreased levels of HDLs [7]. This relationship may improve risk stratification in COPD, and inform a multidisciplinary approach to all integrative therapeutic recommendations made in support of these patients. By extension, this has the potential to lower cardiovascular risk and yield better overall outcomes. We aimed to measure differences in lipid levels according to GOLD-defined severity grades in COPD, and whether individual lipid fractions are significantly associated with COPD severity. This paper therefore seeks to reconcile

pulmonary and metabolic approaches to this complex, with the view of enhancing an integrated model of COPD management in a jurisdiction where the burden of COPD and metabolic abnormalities is rising [8, 9].

## MATERIAL AND METHODS

This Cross-Sectional Study Involved 100 adult patients (40 years or above) having physician-diagnosed COPD and were recruited between Aug 2023- Jan 2024 at the Department of Medicine, Med Clinic, Al Noor Hospital, Abu Dhabi to determine the severity of COPD in accordance with GOLD staging (mild, moderate, severe, and very severe) after obtaining written informed consent. Venous blood samples were collected for measurement of serum lipid parameters. to use in measurement of serum total cholesterol, LDL-C, HDL- C, and triglycerides using standard enzymatic assays. We used the means and standard deviations, as well as correlations between lipid parameters and the severity of COPD which were determined by Pearson correlation coefficient. Sample statistics were done by SPSS version 24.0 with  $p < 0.05$  as the significance level, two-sided.

## ETHICAL APPROVAL STATEMENT

This study was approved by the Institutional Review Board of Al Noor Hospital, Abu Dhabi, UAE (**IRB No. ANH-IRB/2022/219**). All participants provided written informed consent prior to enrollment. The research adhered to the ethical principles of the Declaration of Helsinki, ensuring confidentiality and patient rights.

## INCLUSION CRITERIA

Patients who were 40 years or above with clinically and Spirometrically proven COPD (post bronchodilator FEV<sub>1</sub>/FVC:  $< 0.70$ ) who consented were included.

## EXCLUSION CRITERIA

Excluded were patients with active infection, significant COPD flare and well-known cardiovascular disease and patients taking lipid-lowering medications or had any condition that alters lipid metabolism (e.g., hypothyroidism, nephrotic syndrome).

## DATA COLLECTION

The demographic data, smoking history, as well as Spirometric measures were taken. Blood was drawn using a

venipuncture method in a fasting state and tested in the accredited laboratory in the hospital according to the standardized procedures and quality testing: the total cholesterol, LDL-C, HDL-C, and the level of triglycerides.

**STATISTICAL ANALYSIS**

SPSS version 24.0 was used to analyses all data. All variables were computed with descriptive statistics. Pearson correlation coefficient was used to measure the interrelationship between serum lipid levels and COPD severity. ANOVA or t-tests were used to compare groups in relation to GOLD stages, and  $p < 0.05$  (two-tailed) was chosen as the level of significance.

**RESULTS**

100 patients with COPD were involved (60 male, 40

female) with the average age of  $62 \pm 8$  years. The lowest number distributed in eight stages of GOLD was (n=20; mild), (n=30; moderate), (n=35; severe) and (n=15; very severe). The mean total cholesterol rose with severity of the disease mild  $200 \pm 20$  mg/dl., moderate  $220 \pm 25$  mg/dl., severe  $245 \pm 30$  mg/dl., very severe  $260 \pm 35$  mg/dl. ( $p < 0.01$ ). 45 % of severe and 60 percent of very severe patients had elevated total cholesterol ( $>240$  mg/LD.). Mean LDL-C showed the same tendency: mild  $120 \pm 15$  mg/dl., moderate  $135 \pm 18$  mg/dl., severe  $150 \pm 20$  mg/dl., very severe  $165 \pm 22$  mg/dl. ( $p = 0.02$ ). LDL-C was elevated in 50 % of the severe /very severe group; HDL-C was significantly lower in more severe COPD (mild  $45 \pm 6$  mg/dl., moderate  $40 \pm 5$  mg/dl., severe  $35 \pm 6$  mg/dl., very severe  $30 \pm 5$  mg/dl.,  $p < 0.05$ ); 60 % of severe/very severe patients had HDL-C less than 40 mg/dl. Triglycerides increased with increased COPD severity

**Table 1. Demographic Characteristics of the Study Population (n=100)**

Age (years)	62 ± 8
Gender (Male/Female)	60 (60%) / 40 (40%)
Smoking history (%)	70 (70%) smokers
BMI (kg/m <sup>2</sup> )	26.5 ± 3.2

**Table 4. Proportion of Patients with Abnormal Lipid Values**

Total Cholesterol > 240 mg/dl.	40 (40%)
LDL-C > 160 mg/dl.	25 (25%)
HDL-C < 40 mg/dl.	60 (60%)
Triglycerides > 150 mg/dl.	40 (40%)

**Table 2. Distribution of Patients According to GOLD Stages of COPD**

Mild (Stage I)	20 (20%)
Moderate (II)	30 (30%)
Severe (III)	35 (35%)
Very Severe (IV)	15 (15%)

**Table 5. Correlation between Lipid Parameters and COPD Severity**

Total Cholesterol	0.45	<0.01
LDL-C	0.40	0.02
HDL-C	-0.38	<0.05
Triglycerides	0.35	0.03

**Table 3. Mean Serum Lipid Profile across GOLD Stages**

Total	200 ±	220 ±	245 ±	260 ±	P.VALUE
Cholesterol (mg/dl.)	20	25	30	35	1
LDL-C (mg/dl.)	120 ± 15	135 ± 18	150 ± 20	165 ± 22	0.02
HDL-C (mg/dl.)	45 ± 6	40 ± 5	35 ± 6	30 ± 5	<0.05
Triglycerides (mg/dl.)	130 ± 20	140 ± 18	160 ± 22	170 ± 25	0.03

**DISCUSSION**

The current study proves that there is a strong correlational pattern between COPD severity and lipid abnormalities in the serum samples, which shows an increase total cholesterol, LDL-C, and triglycerides levels and a decrease in HDL-C levels among more severe diseased patients. This result supports the consideration of metabolic and cardiovascular risk factors in COPD management as well as previous findings indicating that COPD is not just a pulmonary disease, but also a systemic inflammatory disorder with far-reaching metabolic implications. Indeed, past

literature has also consistently reported that dyslipidemia is common among patients with COPD. Another large population-based study carried out in China, found that there was a significant increase in the mean total cholesterol and LDL levels among COPD patients than controls of their respective age [10]. Likewise, one study carried out by Gann et al. concluded that systemic inflammation in COPD was linked to an increase in the concentrations of serum lipids implying that changes in lipids could serve as an indicator of low-grade persistent inflammation [11]. Our data goes in line with these observations, especially the high positive correlation between LDL-C and COPD severity. Decreased levels of HDL-C, which we observed in our patients, have been identified in several studies. Decrier et al. provided evidence that COPD patients had considerably low HDL value than their controls did, and the changes in HDL were associated with systemic inflammation, as well as cardiovascular events in a European cohort [12]. HDL has protective properties based upon both reverse cholesterol transport and anti-inflammatory response; a decrease in HDL can therefore impact cardiovascular pathology and exacerbate poor pulmonary outcomes in COPD patients. This corresponds to the data that HDL was  $<40$  mg/dl. in 60% of patients in severe/very severe groups in our data. In our sample of severe COPD patients, 40% had triglycerides  $>150$  mg/LD. This is similar to a study done in India, in which raised triglycerides were much more prevalent in patients with GOLD III and IV disease [13]. The trends found by another cross-sectional study, conducted in Saudi Arabia, are similar because the study indicated that hypertriglyceridemia has a close connection to the prevalence of COPD, especially in older men who have a history of smoking [14]. In conjunction with our results, these data provide bias against the view that triglyceride deregulation is a significant metabolic factor in pathophysiology of COPD in Middle Eastern populations. Lipid peroxidation in COPD Systolic and cardiovascular inflammation are characteristic of chronic obstructive pulmonary disease (COPD), and they enhance the oxidative peroxidation of lipids, altering the physiology of their lipoproteins [15]. Furthermore, hepatic synthesis of lipids and changes in the metabolism of lipoproteins could be triggered by hypoxia in severe COPD, in addition to raising the

serum concentration of cholesterol and triglycerides [16]. Alternatively, chronic sustained systemic corticosteroid exposure may also be involved in the pathogenesis of lipid abnormalities in COPD patients, but as none of the subjects participating in our study were receiving lipid-lowering drugs, pharmacologic confounding by this factor should be eliminated. Cardiovascular comorbidities continue to be the most frequent cause of mortality in COPD and dyslipidemia is a risk factor that can be improved. Muller ova et al. conducted another study that showed a nearly two-fold increase in cardiovascular events in the patients with abnormal lipid profile than those who did not have abnormalities [17]. The results of our study showing that lipid abnormalities actually get worse as severity of COPD increases supports the importance indeed of cardiovascular risk proactive measurement and management in this population. In an interesting turn of events, conflicting results have been recorded in some studies. COPD patients can experience weight loss and decreased levels of BMI and lipids to systemic wasting and catabolism, a cohort study of Japanese patients indicated [18]. Nevertheless, this variation can be connected with the peculiarities of the population, nutrition and predisposition. Most of the patients in our sample were overweight or could be classified as having a normal BMI, which might be one of the reasons why dyslipidemia developed with advanced stages of the disease. Our study has large clinical implications. Although COPD treatment is associated with improved lung function and minimization of exacerbation, our results support the idea of including metabolic screening tests as a standard procedure. Lipid abnormality screening, specifically of LDL and HDL, might enable clinicians to detect patients at high risk who could then be offered preventative treatment at an early stage through lifestyle change or a lipid-lowering agent. The holistic paradigm can not only diminish cardiovascular morbidity but also possibly inhibit systemic inflammation that enhances the advances of COPD [19,20]. There are limitations to our study. Due to their cross-sectional nature, causality cannot be determined, and, therefore, longitudinal investigations are necessary to determine whether dyslipidemia is a factor that can hasten the process of COPD or only represents a comorbidity. Also, patterns of nutrition, physical exercise and socioeconomic aspects capable of affecting lipid

Metabolism, were not measured in our study. Notwithstanding these limitations, our findings contribute to the growing body of evidence linking metabolic deregulation with severity of in brief, our results support those of previous studies but also introduce evidence regarding the UAE context, where both COPD and metabolic syndrome continue to increase[21].The presented correlation between COPD severity and lipid abnormalities is important in illustrating the need to take on a multidisciplinary approach to caring about patients, where pulmonary rehabilitation is coupled with cardiovascular and metabolic risk-management strategies. Prospective longitudinal and interventional studies are also needed to investigate whether correction of dyslipidemia would translate into a benefit in COPD and overall mortality [22-23].

## LIMITATIONS

The limitation of our study is a cross-sectional one, which does not allow inferring the causality. Generalizability is limited by the small size of the single-center sample. Lifestyle issues like diet, exercises and socioeconomic status that can have an implication to how the body processes lipids were not established. These associations must be confirmed with longitudinal studies.

## CONCLUSION

It is indicated in this study that dyslipidemia has an important correlation with the severity of COPD. High total and LDL and triglycerides and low HDL were common in moderate-severe cases. These results indicate that both pulmonary and metabolic approaches should be involved in COPD management in terms of paying attention to the lipid profile assessment to minimize the risk of cardiovascular events and increase patient outcomes.

## FUTURE DIRECTIONS

Prospective, multicenter study in a bigger population should be conducted in the future and confirm the findings. Interventional studies examining possibility of lipid-modifying treatment on the basis of improvement of COPD are justified. It may also be additionally suggested that genetic, nutritional, and environmental factors that are involved in lipid metabolism can be investigated in the identification of the aspects that contribute more to the understanding of the relationship between dyslipidemia and the development of COPD and cardiovascular diseases.

### Authors Contribution

**Concept & Design of Study:** Muhammad Ibrahim

**Drafting:** Mohammad Kamran

**Data Collection & Data Analysis:** Khalil

**Critical Review:** Izhar Ahmad

**Final Approval of version:** All authors

**CONFLICT OF INTEREST:** Not applicable.

**FUNDING DISCLOSURE:** No external funding was received for this study.

### ETHICAL STATEMENT

Ref.No.ANH- IRB/2022/219

### AI USAGE STATEMENT

AI tools (e.g., ChatGPT) were used for language editing and structuring of the manuscript. The authors take full responsibility for the content and accuracy of the manuscript.

### COPYRIGHT STATEMENT

© 2025 The Author(s). This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are properly cited.

### DATA AVAILABILITY STATEMENT

All data generated or analyzed during this study are available from the corresponding author upon reasonable request.

## REFERENCE

1. Ben Anes A, Ben Nasr H, Tabka Z, Tabka O, Zaouali M, Chahed K. Plasma lipid profiling identifies phosphatidylcholine 34:3 and triglyceride 52:3 as markers associated with disease severity in COPD. *Lung*. 2022;200:495–503. doi:10.1007/s00408-022-00552-z.
2. Brikman S, Dori G. Sodium-glucose cotransporter-2 inhibitors as a potential treatment in pulmonary disease with CO<sub>2</sub> retention. *Med Hypotheses*. 2020;139:109631. doi:10.1016/j.mehy.2020.109631.
3. Chernetska NV, Stupnytska HY, Fediv OL. Role of MDR1 gene polymorphism in COPD with type 2 diabetes mellitus. *J Med Life*. 2020;13:349–55. doi:10.25122/jml-2020-0139.
4. Entrenas-Castillo M, Salinero-González L, Entrenas-Costa LM, Andújar-Espinosa R. Calcifediol in respiratory disease. *Nutrients*. 2022;14:2447. doi:10.3390/nu14122447.
5. Fekete M, Szarvas Z, Fazekas-Pongor V, Lehoczki A, Tarantini S, Varga JT. Effects of omega-3 supplementation on lipid profile and COPD outcomes. *Ann Palliat Med*. 2022;11:2819–29. doi:10.21037/apm-22-254.
6. He Y, Wang S, Li Y, Deng J, Huang L. Atorvastatin suppresses pulmonary vascular remodeling in COPD. *Clinics (Sao Paulo)*. 2023;78:100252. doi:10.1016/j.clinsp.2023.100252.
7. Jiang L, Li F, Sun J, Huo H, Li X, Li H. Effect of Yiqigubiao pill on COPD in rat models. *J Tradit Chin Med*. 2020;40:983–91. doi:10.19852/j.cnki.jtcm.20201104.001.
8. Jolliffe DA, Stefanidis C, Wang Z, Kermani NZ, Dimitrov V, White JH, et al. Vitamin D metabolism in COPD and asthma. *Am J Respir Crit Care Med*. 2020;202:371–82. doi:10.1164/rccm.201909-1867OC.
9. Kim KS, Park S. Polygenic risk scores and COPD risk interaction with omega-3 intake. *Nutrients*. 2023;15:3062. doi:10.3390/nu15133062.
10. Kuang X, Wang Y, Liu S, Chang L, Yin Y, Li Z, et al. Tongxinluo enhances atorvastatin effect in COPD-related atherosclerosis. *Food Sci Nutr*. 2023;11:390–407. doi:10.1002/fsn3.3070.
11. Li Q, Wong W, Birnberg A, Chakrabarti A, Yang X, Choy DF, et al. Lysophosphatidic acid species and COPD exacerbations. *BMC Pulm Med*. 2021;21:301. doi:10.1186/s12890-021-01670-9.
12. Mohammadtursun N, Li Q, Abuduwaki M, Jiang S, Zhang H, Sun J, et al. Loki zupa in cigarette smoke-induced COPD model. *Chin Med*. 2020;15:92. doi:10.1186/s13020-020-00373-3.
13. Serban KA, Pratte KA, Strange C, Sandhaus RA, Turner AM, Beiko T, et al. Biomarkers for emphysema in COPD. *EBioMedicine*. 2022;84:104262. doi:10.1016/j.ebiom.2022.104262.
14. Sierkova VK, Romanova V, Lilevska AA, Savytska OO. Role of lipoprotein(a) in coronary heart disease in COPD patients. *Wiad Lek*. 2020;73:2489–93.
15. Vietri L, Fui A, Bergantini L, d'Alessandro M, Cameli P, Sestini P, et al. Serum amyloid A as a biomarker in lung disease. *Respir Investig*. 2020;58:21–7. doi:10.1016/j.resinv.2019.09.005.
16. Wang D, Rao L, Lei H, Li W, Yu Q, Li W, et al. Serum 14-3-3 $\beta$  protein in COPD. *Sci Rep*. 2023;13:4861. doi:10.1038/s41598-023-32096-4.
17. Wang J, Ren C, Jin L, Batu W. Seabuckthorn formulation in COPD via gut microbiota pathway. *J Ethnopharmacol*. 2023;314:116591. doi:10.1016/j.jep.2023.116591.
18. Wang T, Chen X, Li H, Chen W, Xu Y, Yao Y, et al. Prothrombotic changes in COPD and lipid peroxidation. Part Fibre Toxicol. 2022;19:65. doi:10.1186/s12989-022-00503-9.
19. Wang Y, Chang C, Tian S, Wang J, Gai X, Zhou Q, et al. Lipid metabolism in COPD exacerbations. *Front Mol Biosci*. 2023;10:1204985. doi:10.3389/fmolb.2023.1204985.
20. Wang Y, Kuang X, Yin Y, Han N, Chang L, Wang H, et al. Tongxinluo prevents COPD with atherosclerosis. *Biomed Pharmacother*. 2022;145:112367. doi:10.1016/j.biopha.2021.112367.
21. Xue M, Cai C, Guan L, Xu Y, Lin J, Zeng Y, et al. Polyunsaturated fatty acids in severe COPD. *Int J Chron Obstruct Pulmon Dis*. 2020;15:1633–42. doi:10.2147/COPD.S245617.
22. Yoshida M, Hiramoto T, Moriwaki A, Osoreda H, Iwanaga T, Inoue H. Extrapulmonary comorbidities and COPD. *PLoS One*. 2022;17:e0270836. doi:10.1371/journal.pone.0270836.
23. Zhao T, Wang C, Duan B, Yang P, Wu J, Zhang Q. Altered lipid profile in COVID-19 and metabolic changes. *Front Microbiol*. 2022;13:863802. doi:10.3389/fmicb.2022.863802.